Abstract
Evi-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells1,2,3,4,5. Evi-1 has two zinc-finger domains, one with seven repeats of a zinc-finger motif and one with three repeats6, and it has characteristics of a transcriptional regulator7,8. Although Evi-1 is thought to be able to promote growth and to block differentiation in some cell types9,10,11, its biological functions are poorly understood. Here we study the mechanisms that underlie oncogenesis induced by Evi-1 by investigating whether Evi-1 perturbs signalling through transforming growth factor-β (TGF-β), one of the most studied growth-regulatory factors, which inhibits proliferation of a wide range of cell types12. We show that Evi-1 represses TGF-β signalling and antagonizes the growth-inhibitory effects of TGF-β. Two separate regions of Evi-1 are responsible for this repression; one of these regions is the first zinc-finger domain. Through this domain, Evi-1 interacts with Smad3, an intracellular mediator of TGF-β signalling13, thereby suppressing the transcriptional activity of Smad3. These results define a new function of Evi-1 as a repressor of signalling through TGF-β.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lopingco, M. C. & Perkins, A. S. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Cur. Top. Microbiol. Immunol. 211, 211–222 (1996).
Morishita, K. et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc. Natl Acad. Sci. USA 89, 3937–3941 (1992).
Mitani, K. et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13, 504–510 (1994).
Ogawa, S. et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 13, 183–191 (1996).
Ogawa, S. et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 10, 788–794 (1996).
Morishita, K. et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54, 831–840 (1988).
Tanaka, T. et al. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J. Biol. Chem. 269, 24020–24026 (1994).
Bartholomew, C., Kilbey, A., Clark, A. M. & Walker, M. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 14, 569–577 (1997).
Kurokawa, M. et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 11, 833–840 (1995).
Morishita, K., Parganas, E., Matsugi, T. & Ihle, J. N. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol. Cell. Biol. 12, 183–189 (1992).
Kreider, B. L., Orkin, S. H. & Ihle, J. N. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc. Natl Acad. Sci. USA 90, 6454–6458 (1993).
Massagué, J. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6, 597–641 (1990).
Zhang, Y., Feng, X., We, R. & Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383, 168–172 (1996).
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F. & Massagué, J. Mechanism of activation of the TGF-β receptor. Nature 370, 341–347 (1994).
Macias-Silva, M. et al. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87, 1215–1224 (1996).
Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257–261 (1994).
Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M. & Massagué, J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62, 175–185 (1990).
Derynck, R. & Zhang, Y. Intracellular signalling: the mad way to do it. Curr. Biol. 6, 1226–1229 (1996).
Massagué, J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 85, 947–950 (1996).
Wrana, J. L. & Attisano, L. MAD-related proteins in TGFβ signaling. Trends Genet. 12, 493–496 (1996).
Wu, R.-Y., Zhang, Y., Feng, X.-H. & Derynck, R. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol. Cell. Biol. 17, 2521–2528 (1997).
Nakao, A. et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16, 5353–5362 (1997).
Wieser, R., Wrana, J. L. & Massagué, J. GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14, 2199–2208 (1995).
Yingling, J. M. et al. Tumor suppressor Smad4 is a transforming growth factor β-inducible DNA binding protein. Mol. Cell. Biol. 17, 7019–7028 (1997).
Tanaka, T. et al. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol. Cell. Biol. 15, 2383–2392 (1995).
Lagna, G., Hata, A., Hemmati, B. A. & Massagué, J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature 383, 832–836 (1996).
Hata, A. S. L. R., Wotton, D., Lagna, G. & Massagué, J. Mutations increasing autoinhibition inactive tumor suppressors Smad2 and Smad4. Nature 388, 82–87 (1997).
Takebe, Y. et al. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8, 466–472 (1988).
Kurokawa, M. et al. Aconserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts. J. Biol. Chem. 271, 16870–16876 (1996).
Acknowledgements
We thank J. Massagué for Smad1–Flag and Smad4–HA; J. L. Wrana for Smad2–Flag and the pCMV5 vector; R. Derynck for Smad3–Flag and Smad4-Flag; X.-F. Wang for p15P113–Luc; K.Miyazono for p3TP–Lux and TβRI TD; and K. Arai for pME18Sneo. This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health and Welfare and from the Ministry of Education, Science, and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kurokawa, M., Mitani, K., Irie, K. et al. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 394, 92–96 (1998). https://doi.org/10.1038/27945
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/27945
This article is cited by
-
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
Journal of Ovarian Research (2023)
-
Comprehensive characterization of TGFB1 across hematological malignancies
Scientific Reports (2023)
-
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia
Signal Transduction and Targeted Therapy (2023)
-
Transcriptome analysis of human dermal fibroblasts following red light phototherapy
Scientific Reports (2021)
-
Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities
Modern Pathology (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.